ZURAWSKI, GERARD,ZURAWSKI, SANDRA,NI, LING,OH, SANKON,BANCHEREAU, JACQUES F
申请号：
NZ59489208
公开号：
NZ594892A
申请日:
2008.02.22
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is the use of a Dectin-1/TLR9 activated dendritic cell in conjunction with one or more antigens for treating a disease by enhancing T cell or B cell immune responses in the manufacture of a medicament, wherein the disease is selected from viral disease, bacterial diseases, fungal diseases, protozoa diseases, parasitic diseases, tumours, autoimmune diseases, allergies or graft rejection wherein manufacture comprises triggering a Dectin-1 receptor on a dendritic cell with a Dectin-1 specific antibody or functional fragment thereof in conjunction with one or more antigens and an activator of TLR9 wherein the anti-Dectin-1-specific antibody or functional fragment thereof is capable of activating the dendritic cell wherein the one or more antigens are selected from the group consisting of viral antigens, bacterial antigens, fungal antigens, protozoal antigens, parasitic antigens, tumor antigens, antigens involved in autoimmune disease, antigens involved in allergy, and antigens involved in graft rejection.
